Anti-N-methyl-D-aspartate receptor autoimmune encephalitis represents a devastating neuroinflammatory disorder that predominantly affects young adults and pediatric populations. The disease process causes severe psychiatric manifestations, autonomic dysfunction, refractory status epilepticus, and profound cognitive impairment. Although acute first-line immunotherapies such as high-dose intravenous corticosteroids, intravenous immunoglobulin, and therapeutic plasma exchange stabilize many individuals, a substantial subset of patients demonstrates inadequate recovery. Consequently, clinicians must promptly escalate care to second-line therapies to prevent irreversible neuronal sequelae. While intravenous rituximab has historically served as the benchmark second-line agent, its chimeric structure carries notable risks of infusion reactions and requires protracted hospital-based administration. Recent clinical investigations have explored whether newer B-cell depleting agents can address these practical limitations. Emerging multicenter clinical trial data now provide compelling support for the therapeutic role of ofatumumab in autoimmune encephalitis, providing clinicians with a potent, subcutaneous alternative to standard escalation regimens.

The Clinical Rationale for Ofatumumab in Autoimmune Encephalitis

Pathogenic autoantibodies in anti-NMDA receptor encephalitis directly target the extracellular GluN1 subunit of the receptor, driving receptor internalization and devastating synaptic hypofunction. Therefore, rapid and profound depletion of antibody-secreting CD20-positive B-cell lineages represents the cornerstone of disease-modifying intervention. Ofatumumab is an advanced, fully human second-generation anti-CD20 immunoglobulin G1 monoclonal antibody. Crucially, the molecule binds specifically to a novel, distinct epitope incorporating both the small and large extracellular loops of the CD20 transmembrane protein. This distinct spatial binding geometry brings the antibody closer to the cell membrane surface, markedly increasing complement-dependent cytotoxicity compared to first-generation chimeric agents. Furthermore, because ofatumumab possesses a completely humanized amino acid sequence, it significantly minimizes the formation of neutralizing anti-drug antibodies. The agent also markedly diminishes the incidence of severe hypersensitivity responses. Most importantly, the convenient subcutaneous route of delivery bypasses the necessity for prolonged intravenous infusion chairs, thereby expediting systemic drug exposure and facilitating rapid therapeutic immunomodulation in critical neuro-intensive settings.

Design and Methodology of the Prospective OFF-AE Study

To establish rigorous comparative evidence, researchers initiated the prospective, multicenter, nested cohort study designated as OFF-AE. Investigators systematically recruited participants from the comprehensive CHina Autoimmune encephalitiS outcomE (CHASE) registry between October 2011 and February 2024. From an initial screening pool of 715 patients presenting with autoimmune encephalitis, investigators identified confirmed cases of anti-NMDA receptor encephalitis and stratified them based on whether they received ofatumumab or conventional alternative regimens. To effectively neutralize treatment selection bias and eliminate confounding clinical variables, the investigators executed a rigorous propensity score matching protocol. Ultimately, the researchers established two well-balanced cohorts comprising 58 propensity score-matched patients in the ofatumumab treatment arm and 58 matched controls in the non-ofatumumab arm. The primary clinical endpoint evaluated the proportion of patients attaining a favorable functional outcome, defined strictly as a modified Rankin Scale (mRS) score of 2 or lower at the final clinical follow-up. Secondary endpoints tracked longitudinal improvements using the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score across a 24-month observation window.

Key Findings: Rapid Functional Recovery and Superior Efficacy

The clinical results from the prospective cohort demonstrated striking neurological benefits following ofatumumab administration. Among patients treated with ofatumumab, an impressive 93.1% (54 of 58 patients) achieved demonstrable functional improvement on the modified Rankin Scale, exhibiting a remarkably brief median response time of only 14 days from treatment initiation. Furthermore, 91.4% of patients in the ofatumumab cohort attained a favorable functional outcome (mRS score ≤2) at their last clinical evaluation. The therapeutic advantage became exceptionally prominent among patients who had previously failed standard first-line therapies. In this challenging refractory subgroup, patients receiving ofatumumab demonstrated significantly accelerated rates of recovery in both mRS and CASE scores compared to their non-ofatumumab counterparts. Specifically, 87.9% of refractory patients treated with ofatumumab reached favorable long-term functional status, compared to only 64.7% in the comparator group. This difference represented an adjusted odds ratio of 3.95 (95% confidence interval, 1.12 to 13.94; p = 0.026), demonstrating significant clinical superiority over conventional salvage options.

Safety Profile and Tolerability in Acute Neuroinflammatory Disease

Safety represents a paramount consideration when administering potent immunomodulatory agents to critically ill neurological patients. Encouragingly, the OFF-AE study reported an exemplary tolerability profile, recording zero treatment-related serious adverse events among individuals receiving ofatumumab. Conventional intravenous CD20-targeted regimens frequently trigger acute infusion-related reactions, bronchospasm, and hemodynamic fluctuations that require intensive pre-medication and continuous cardiovascular monitoring. In contrast, subcutaneous ofatumumab produced minimal systemic reactivity, with patients occasionally experiencing only transient, mild injection-site discomfort or low-grade pyrexia that resolved spontaneously. In addition, peripheral CD19 and CD20 B-cell counts decreased rapidly to undetectable levels without inducing unexpected opportunistic infections or severe neutropenia during long-term follow-up. Consequently, the subcutaneous route reduces direct nursing workload, eliminates prolonged vascular access complications, and mitigates the clinical instability often observed during prolonged intravenous infusions in agitated or encephalopathic patients. These favorable pharmacological characteristics position ofatumumab as an attractive therapeutic option for acute inpatient wards and intensive care units alike.

Translating Evidence into Neurological Clinical Pathways

Integrating these landmark findings into hospital management protocols offers substantial practical benefits for acute neurology teams. When treating confirmed anti-NMDA receptor encephalitis, clinicians generally assess therapeutic response within 10 to 14 days following initiation of first-line pulse steroids or intravenous immunoglobulins. If the patient demonstrates clinical plateauing or progressive neurological worsening, clinicians should not delay escalation to second-line B-cell depletion. The documented median time to improvement of two weeks highlights that ofatumumab acts swiftly, helping suppress neuroinflammation before structural synaptic remodeling occurs. Additionally, the pre-filled subcutaneous autoinjector format allows straightforward bedside delivery, even in highly monitored intensive care settings where venous access sites remain heavily congested with essential vasoactive infusions. Physicians should nonetheless conduct thorough baseline screening, including tests for latent tuberculosis, hepatitis B surface antigen, and baseline immunoglobulin levels, prior to administering the initial loading dose. By implementing structured escalation protocols, neurocritical care units can systematically improve functional survival while minimizing long-term neurocognitive deficits.

Future Directions and Broader Implications for Neuroimmunology

Although the OFF-AE prospective cohort study delivers compelling observational data, future research must continue expanding our understanding of optimized B-cell therapies. Investigators should ideally conduct randomized, double-blind clinical trials to directly compare subcutaneous ofatumumab against standardized weight-based intravenous rituximab regimens. Furthermore, subsequent studies must clarify whether sustained low-dose maintenance schedules prevent late disease relapses, which historically afflict up to 25% of autoimmune encephalitis survivors. Clinicians also require refined biomarker strategies, such as serial monitoring of cerebrospinal fluid antibody titers and circulating neurofilament light chain concentrations, to tailor therapy duration precisely. Nevertheless, the findings from this landmark study signal a major paradigm shift in neuroimmunological care. By demonstrating robust efficacy, exceptionally rapid clinical stabilization, and minimal systemic toxicity, ofatumumab expands the modern therapeutic armamentarium, offering renewed hope for patients battling severe, refractory autoimmune encephalitis across global clinical practice.

Frequently Asked Questions

How does ofatumumab differ mechanically from rituximab in autoimmune encephalitis?

Ofatumumab is a fully human monoclonal antibody that binds directly to unique proximal epitopes on the CD20 receptor, generating significantly higher complement-dependent cytotoxicity than chimeric rituximab. Moreover, its subcutaneous formulation minimizes immunogenicity, prevents anti-chimeric antibody neutralization, and eliminates the severe systemic infusion reactions frequently encountered with intravenous rituximab infusions.

How quickly can clinicians expect neurological recovery after starting ofatumumab?

Patients typically exhibit initial neurological improvements rapidly following treatment initiation. In the prospective OFF-AE cohort study, 93.1% of patients achieved measurable improvements in modified Rankin Scale scores, with a median response onset of just 14 days, demonstrating much faster symptom stabilization compared to traditional salvage strategies.

What pre-treatment laboratory screening is mandatory before administering ofatumumab?

Clinicians must thoroughly evaluate patients for latent infections before treatment. Standard workups include complete hepatitis B serologies, hepatitis C screening, tuberculosis interferon-gamma release assays, quantitative serum immunoglobulin levels, and complete blood counts. Clinicians must actively monitor these baseline parameters to ensure safety and prevent secondary opportunistic reactivation during profound B-cell depletion.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or replace professional healthcare judgment. Clinical decisions must always be tailored to the individual patient's clinical circumstance and should be guided by qualified healthcare professionals. Refer to the latest local and national guidelines for clinical practice.

References

Guo K et al. Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study. Ann Neurol. 2025 Jul. doi: 10.1002/ana.27218. PMID: 39991981.

Deng M, Xiong J, Hu D, Kong Z, Li T. Case report: efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review. Front Immunol. 2025;16:1557210. doi: 10.3389/fimmu.2025.1557210.

Seery N, Wesselingh R, Beech P, et al. Rituximab use for relapse prevention in anti-NMDAR antibody-mediated encephalitis: A multicenter cohort study. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200395. doi: 10.1212/NXI.0000000000200395.